NASDAQ OMX

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

Del

--  Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases

  --  Leaders from local government, life sciences and medical technology to join on October 4 for dedication of first anticipated gene and cell therapy production center in Ohio

CLEVELAND, Oct. 04, 2017 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today the ground-breaking of the first anticipated commercial gene therapy manufacturing facility in Ohio. The Cleveland-based facility, named The Elisa Linton Center for Rare Disease Therapies, will have the capacity to produce advanced gene and cell therapies to treat serious and debilitating rare diseases. The dedication and ground-breaking ceremony is being held today, October 4, 2017.  

"We are very excited to announce the creation of The Elisa Linton Center for Rare Disease Therapies, which will be a global resource for production of gene therapies with the potential to bring new treatments to rare disease patients around the world," said Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics. "It is especially fitting that this center is named for Elisa Linton, who was born with Sanfilippo syndrome, a rare terminal disease. The memory of Elisa and courage of her family continue to be a great inspiration to all members of the rare disease community."

The Elisa Linton Center for Rare Disease Therapies will initially be used to produce ABO-101 and ABO-102, investigational gene therapies currently in development at Abeona for the treatment of patients with Sanfilippo syndrome, and EB-101, an investigational autologous cell therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare and devastating skin disorder. The Center will also house Abeona's expanded viral-vector lab, which will develop and produce unique and proprietary vectors used for the delivery of gene therapies. The 6,000 square foot Center will be built-out and validated over the next 12 months.

"The Epidermolysis Bullosa Medical Research Foundation, along with the EB Research Partnership, is a longtime supporter of research that may help patients living with EB including the development of EB-101. The development of EB-101 is a great example of the progress we are making in EB research today," said Paul Joseph, Chief Financial Officer of the Epidermolysis Bullosa Medical Research Foundation. "We are very pleased to support Abeona taking steps to establish a world-class gene therapy production facility that will bring new hope to people living with EB and other serious diseases and conditions."

Several leaders from local government and life sciences are scheduled to attend the dedication ceremony of the Center, including representatives from United States Senator Sherrod Brown's office, Case Western Reserve University, BioEnterprise, MidTown Cleveland, Inc. and JumpStart Inc.

"Today's groundbreaking celebration represents another successful investment in Ohio innovation and manufacturing," said Senator Brown. "It's exciting to see investments in gene therapy treatments for rare diseases happening right here in Cleveland, helping to cement Ohio's leadership in the healthcare and technology industries. Today's ceremony is another step forward for the health of rare disease patients and for the strength of the region's economy."

"We applaud Abeona's decision to open a state-of-the-art gene therapy facility in Cleveland's Health-Tech Corridor," said Aram Nerpouni, President and CEO of BioEnterprise. "The Cleveland bioscience industry has grown remarkably in the past decade and Abeona's investment is a potent example of our region's momentum. We look forward to our ongoing relationship with Abeona and other emerging bioscience companies that continue to grow and strengthen our local economy."

About EB Medical Research Foundation: As the leader in research funding, the Epidermolysis Bullosa Medical Research Foundation is an all-volunteer, non-profit 501(c) Foundation dedicated to funding research for Epidermolysis Bullosa to determine its causes, develop successful treatments, and ultimately find a cure. EB is a rare, debilitating and often fatal genetic disorder which causes painful scarring and blistering of the skin and internal organs. Our continued goal is to raise awareness through special events, the media and fundraising programs. www.ebmrf.org

About BioEnterprise: BioEnterprise is a business formation, recruitment, and acceleration effort designed to support the growth of bioscience companies. Located in Cleveland, BioEnterprise provides management counsel and support services to health IT, medical device, and biopharmaceutical companies. BioEnterprise founders are Case Western Reserve University, Cleveland Clinic, and University Hospitals. Additional technology partners include the NASA Glenn Research Center, Cleveland State University, and BioOhio. The initiative comprises the collective activities of BioEnterprise and its partners' commercialization offices: The Case Office of Technology Transfer, Cleveland Clinic Innovations, and University Hospitals Cleveland - Center for Clinical Research. The combined efforts of these groups has created, recruited, and accelerated more than 300 companies in 15 years. For more information: www.BioEnterprise.com.

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).  Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a proprietary vector platform, AIM(TM), for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212) 786-6212
csilverstein@abeonatherapeutics.com

Media Contact: 
Lynn Granito
Berry & Company Public Relations  
+1 (212) 253-8881  
lgranito@berrypr.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that patients will continue to be identified, enrolled, treated and monitored in the EB-101 clinical trial, and that studies will continue to indicate that EB-101 is well-tolerated and may offer significant improvements in wound healing; the addition of two additional global clinical sites will accelerate our ability to enroll and evaluate ABO-102 as a potential treatment for patients with Sanfilippo syndrome type A, or MPS IIIA.  Such statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support our approach for intravenous delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30Pressemelding

CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC.                                                               Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S.  DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12Pressemelding

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On

Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations se

World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16Pressemelding

YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.

New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01Pressemelding

New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct.  17, 2017  (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p

CP Kelco Appoints Didier Viala as New President16.10.2017 15:00Pressemelding

ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom